<DOC>
	<DOCNO>NCT00718861</DOCNO>
	<brief_summary>This second extension evaluate efficacy long term safety zoledronic acid woman post-menopausal osteoporosis</brief_summary>
	<brief_title>3 yr Efficacy &amp; Safety Study Zoledronic Acid Post-menopausal Women With Osteoporosis Treated With Zol Acid 6 Yrs</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Women receive 4th 6th dose zoledronic acid study CZOL446H2301E1 Poor kidney , eye , liver health Use certain therapy osteoporosis study CZOL446H2301E1 Abnormal calcium level Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>zoledronic acid</keyword>
	<keyword>post-menopausal</keyword>
</DOC>